Literature DB >> 21632035

Amyotrophic lateral sclerosis: a neurovascular disease.

Svitlana Garbuzova-Davis1, Maria C O Rodrigues, Diana G Hernandez-Ontiveros, Michael K Louis, Alison E Willing, Cesario V Borlongan, Paul R Sanberg.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease with a complicated pathogenesis. Compelling evidence indicates impairment of all neurovascular unit components including the blood-brain and blood-spinal cord barriers (BBB/BSCB) in both patients and animal models, leading to classification of ALS as a neurovascular disease. The present review provides an updated analysis of the normal and impaired BBB/BSCB, focusing on the ALS-altered barrier. Here we describe the roles of cellular components, tight junctions, transport systems, cell interactions, cytokines, matrix metalloproteinases, and free radicals in the BBB/BSCB disruption, along with recent evidence from experimental and clinical ALS studies. The BBB/BSCB is a promising research area in ALS and this review will reveal some aspects of microvascular pathology in ALS and hopefully provide ideas for the development of new therapeutic strategies.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21632035     DOI: 10.1016/j.brainres.2011.04.049

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  45 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

Review 2.  Systems biology of neurodegenerative diseases.

Authors:  Levi B Wood; Ashley R Winslow; Samantha Dale Strasser
Journal:  Integr Biol (Camb)       Date:  2015-07       Impact factor: 2.192

Review 3.  Cerebrovascular disorders: molecular insights and therapeutic opportunities.

Authors:  Erik Storkebaum; Annelies Quaegebeur; Miikka Vikkula; Peter Carmeliet
Journal:  Nat Neurosci       Date:  2011-10-26       Impact factor: 24.884

Review 4.  Monocyte chemoattractant protein-1 and the blood-brain barrier.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Cell Mol Life Sci       Date:  2013-09-20       Impact factor: 9.261

Review 5.  Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Xin Fang
Journal:  Metab Brain Dis       Date:  2018-04-22       Impact factor: 3.584

Review 6.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

7.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

Review 8.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

Review 9.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

Review 10.  ABC transporter-driven pharmacoresistance in Amyotrophic Lateral Sclerosis.

Authors:  Michael Jablonski; David S Miller; Piera Pasinelli; Davide Trotti
Journal:  Brain Res       Date:  2014-08-28       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.